Quince Therapeutics, Inc. - Common Stock QNCX 深 沪
等待开盘 11-07 09:30:00 美东时间
1.59
+0.010
+0.63%
华盛通- 最 高1.62
- 今 开1.61
- 成交量 22.18万股
- 最 低 1.56
- 昨 收 1.58
- 总市值 8540.49万
- 52周最高 2.45
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 0.7203
- 委 比 63.67%
- 总股本 5371.38万
- 历史最高 121.98
- 量 比 1.35
- 振 幅 3.80%
- 历史最低 0.5116
- 每 手 1
- 风险率 0.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Quince Therapeutics Announces Poster Presentation Of Patient-Reported Walking Capacity In Children With Ataxia-Telangiectasia At 54th CNS Annual Meeting
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of
10-10 04:08
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
Quince Therapeutics Amends Credit Facility Agreement
Quince Therapeutics ( ($QNCX) ) has provided an update. On September 25, 2025, ...
09-27 05:16
Quince Therapeutics Publishes Advanced PK Modeling Study Of Phase 3 Asset eDSP In A-T Patients And Healthy Adults In ASCPT Journal PSP
Quince Therapeutics, Inc.
09-26 04:07
JMP Securities Maintains Market Outperform on Quince Therapeutics, Lowers Price Target to $8
JMP Securities analyst Jonathan Wolleben maintains Quince Therapeutics (NASDAQ:QNCX) with a Market Outperform and lowers the price target from $9 to $8.
08-12 21:12
Quince Therapeutics Q2 EPS $(0.34) Misses $(0.26) Estimate
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 46.88 percent increase over losses of $(0.64) per share
08-12 04:19
JMP Securities Initiates Coverage On Quince Therapeutics with Market Outperform Rating, Announces Price Target of $9
JMP Securities analyst Jonathan Wolleben initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Market Outperform rating and announces Price Target of $9.
08-05 20:40
Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial To Evaluate eDSP For Treatment Of Rare Neurodegenerative Disease Ataxia-Telangiectasia
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed
07-16 20:06
Quince Therapeutics Raises $11.5M in Private Placement
Quince Therapeutics ( ($QNCX) ) has shared an announcement. On June 12, 2025, Q...
06-14 05:46
Quince Therapeutics announces pricing of up to $22M private placement; shares up 22%
Quince Therapeutics (NASDAQ:QNCX) announces a private placement expected to generate $11.5M in upfront proceeds. The deal includes common stock (or pre-funded warrants) and accompanying common warrant...
06-13 05:31
